Financial Summary for Fiscal Year Ending March 2026 [IFRS] (Consolidated)

Overview of Financial Results

For the fiscal year ended March 2026, consolidated revenue amounted to 1,028,171 million yen (up 1.4% YoY). Operating income was 183,615 million yen (down 1.1% YoY), profit before tax was 184,976 million yen (down 0.2% YoY), and net income for the period was 133,537 million yen (down 2.7% YoY). Net income attributable to owners of the parent was 133,498 million yen (down 2.7% YoY). Foreign exchange effects reduced operating income by approximately 8.1 billion yen.

Segment Performance

The Industrial Tape segment recorded revenue of 366,607 million yen (up 4.2% YoY) and operating income of 51,662 million yen (up 12.6% YoY), achieving both revenue and profit growth. The Optronics segment posted revenue of 527,812 million yen (down 2.6% YoY) and operating income of 149,871 million yen (down 13.4% YoY), marking declines in both revenue and profit. The Human Life segment recorded revenue of 143,702 million yen (up 8.5% YoY) and an operating loss of 5,041 million yen (compared to an operating loss of 11,718 million yen in the previous year), reducing its loss margin. Other segments reported revenue of 1,100 million yen (down 40.6% YoY) and an operating loss of 6,971 million yen (compared to an operating loss of 12,229 million yen in the previous year), also narrowing losses.

Dividend Policy and Dividend

A year-end dividend of 30 yen per share is planned for the current term. The annual dividend for the next term is planned at 64 yen (an increase of 4 yen from the previous term), continuing a shareholder return policy with emphasis on dividend payments.

Outlook

For the fiscal year ending March 2027, consolidated forecasts anticipate revenue of 1,065,000 million yen (up 3.6% YoY), operating income of 193,000 million yen (up 5.1% YoY), and net income of 141,000 million yen (up 5.6% YoY). The Industrial Tape segment expects increased demand following the mandatory smartphone repair rights implementation in Europe, while the Optronics segment will monitor semiconductor memory shortages closely and focus on growth areas. The Human Life segment will strengthen production systems toward the commercialization of nucleic acid drugs. ESG management will be promoted with expansion of dual-certified products and structural reforms of low-profit businesses.